science
Redesigned cancer drug triggers immune response across body
April 4, 2026
Summary
A modified CD40 antibody therapy showed promising results in a phase 1 clinical trial, with tumors shrinking in half of 12 patients and two achieving complete remission. Remarkably, injecting the drug into one tumor triggered the immune system to attack cancers elsewhere in the body without the severe side effects seen in earlier trials.
Advertisement
Quick Facts
- Two patients experienced complete remission—all detectable cancer disappeared
- Tumors shrank in six of 12 trial participants across multiple cancer types
- No participants experienced the severe side effects of earlier CD40 therapies
Why It Matters
This approach could expand treatment options for metastatic cancer patients with fewer toxic complications.